Eli Lilly and Company

ticker: LLY step: 01 generated: 2026-05-11 source: quick-research

Eli Lilly and Company (LLY) — Business Overview

Business Description

Eli Lilly is a US-based global pharmaceutical company that has emerged as the dominant force in the incretin (GLP-1 / GIP) class for diabetes and obesity treatment. Its tirzepatide franchise — marketed as Mounjaro (diabetes) and Zepbound (obesity) — has reshaped both the company and the broader cardiometabolic drug market. Beyond cardiometabolic, Lilly is a significant player in oncology, immunology, and Alzheimer's disease, with Kisunla (donanemab) approved for early symptomatic Alzheimer's.

Revenue Model

• Branded pharmaceutical sales (~98% of revenue): Direct sales to pharmacies, hospitals, and PBMs in the US, plus international sales (mostly through subsidiaries). Key franchises include the tirzepatide twins (Mounjaro / Zepbound), Verzenio (oncology), Taltz (immunology), Trulicity (legacy diabetes), Jardiance (diabetes, partnered with Boehringer Ingelheim), Kisunla (Alzheimer's), and Ebglyss (atopic dermatitis).
• Royalty & collaboration income: Partnerships including Boehringer Ingelheim on Jardiance.
• Direct-to-consumer cash-pay: LillyDirect platform sells Zepbound vials directly to self-pay consumers in the US — a structurally important channel that bypasses PBM rebates.

Pricing is largely list-minus-rebate in the US, with growing direct cash-pay share for obesity. International pricing is materially lower; volume is the constraint, not demand.

Products & Services

• Mounjaro (tirzepatide) — Type 2 diabetes (largest franchise, $7.4B in Q4 2025 alone, +110% YoY)
• Zepbound (tirzepatide) — Obesity (US Q4 2025 revenue $4.2B, +122% YoY)
• Trulicity (dulaglutide) — Legacy GLP-1, declining as Mounjaro cannibalizes
• Verzenio (abemaciclib) — Breast cancer
• Taltz (ixekizumab) — Psoriasis / psoriatic arthritis / axial spondyloarthritis
• Jardiance (empagliflozin) — Diabetes (BI-partnered)
• Kisunla (donanemab) — Early symptomatic Alzheimer's
• Ebglyss (lebrikizumab) — Atopic dermatitis
• Pipeline: orforglipron (oral GLP-1, Phase 3 / regulatory submitted), retatrutide (triple agonist), eloralintide, MK-0616 partnership (PCSK9), multiple oncology and Alzheimer's candidates

Customer Base & Go-to-Market

• US (~70% of revenue): Sold through PBMs, retail pharmacies, hospitals, and increasingly direct via LillyDirect. Heavy DTC marketing for Zepbound.
• International (~30% and growing fast): Direct sales subsidiaries in Europe, China, Japan, Latin America; international Zepbound/Mounjaro launches accelerating as manufacturing capacity comes online.
• Hospital and specialty channel: For oncology (Verzenio), immunology (Taltz), and Alzheimer's (Kisunla, infused).
• Payer mix: Commercial insurance, Medicare Part D, Medicaid (heavy rebate exposure), and a fast-growing cash-pay segment.

No single customer represents material concentration; the principal demand-side risk is payer coverage for obesity (Medicare, employer plans).

Competitive Position

Lilly has decisively taken the lead in the incretin class, capturing ~57% of the GLP-1 / GIP market by Q2 2025 (up from ~53% earlier in the year), with Novo Nordisk losing share for the first time. The moat sources are: (1) efficacy — tirzepatide delivers ~20% body weight reduction vs. ~14% for semaglutide; (2) manufacturing scale — Lilly has committed >$50B in US capex (Alabama, Pennsylvania, North Carolina, Europe) and produced 1.6x more salable doses in H1 2025 vs. H1 2024; (3) pipeline depth — orforglipron (oral GLP-1) outperformed oral semaglutide head-to-head and is submitted for approval, retatrutide is the next-generation triple agonist; (4) diversification — oncology, immunology, and Alzheimer's franchises provide non-GLP-1 revenue, unlike Novo's narrower portfolio. Key risks: payer pushback on obesity pricing, MFN executive order pricing pressure, compounded GLP-1 competition (largely curtailed), and longer-term obesity competition from Pfizer, Roche, Amgen, and Viking.

Key Facts

• Founded: 1876
• Headquarters: Indianapolis, IN
• Employees: ~47,000
• Exchange: NYSE
• Sector / Industry: Health Care / Pharmaceuticals
• Market Cap: ~$700B (May 2026)

ticker: LLY step: 04 generated: 2026-05-11 source: quick-research

Eli Lilly and Company (LLY) — Financial Snapshot

Income Statement Summary

Note: FY2023 net income / margin compressed due to large in-process R&D writedowns from the Versanis and POINT Biopharma acquisitions; FY2024 expanded materially as those one-time charges rolled off and tirzepatide ramped.

Cash Flow & Balance Sheet (FY2025)

Key Ratios (approximate, May 2026)

• P/E: ~28x | EV/EBITDA: ~25x | FCF Yield: ~0.7% (suppressed by capex)
• Revenue Growth (TTM): ~45% | Gross Margin: ~83% | Operating Margin: ~39%
• Capex / Revenue: ~17% — Lilly is in the steepest manufacturing build cycle in big-pharma history

Growth Profile

Lilly has gone from ~$28B in revenue in 2022 to ~$65B in 2025 — a roughly 2.3x expansion in three years, almost entirely driven by the tirzepatide franchise (Mounjaro + Zepbound combined run-rate >$45B by end of 2025). The constraint has been supply, not demand: Lilly produced 1.6x more salable doses in H1 2025 vs. H1 2024. Operating leverage is now compounding meaningfully — gross margin remains in the low-80s and operating margin has expanded from 17% (2023, depressed by IPR&D charges) to ~39% (2025). Free cash flow is structurally suppressed by the $50B+ multi-year US manufacturing capex program.

Forward Estimates

2026 guidance (issued Feb 2026): Revenue $80–83B (+25% YoY). Consensus FY2026 EPS: ~$31. Bull-side scenarios pencil in 2027 revenue >$100B if orforglipron (oral GLP-1) launches strongly in H2 2026 and Zepbound DTC volumes ramp. Bear-side scenarios bake in MFN pricing pressure on US obesity prices, slower-than-expected payer expansion, and 2030+ generic erosion of tirzepatide.

ticker: LLY step: 12 generated: 2026-05-11 source: quick-research

Eli Lilly and Company (LLY) — Investment Catalysts & Risks

Bull Case Drivers

1. Orforglipron oral GLP-1 approval (mid-April 2026 PDUFA) — Phase 3 data showed 12–15% weight loss and head-to-head superiority vs. oral semaglutide. A US approval opens a structurally new market: needle-phobic patients, easier global distribution, and a much lower cost-to-manufacture profile than injectables. Bull-case incremental peak revenue estimates range $15–30B and would expand obesity TAM by 2–3x.

2. Retatrutide triple-agonist data readouts through 2026 — Phase 3 TRANSCEND-T2D-1 results at ADA in June 2026, with broader Phase 3 obesity readouts later in the year. Mid-cycle data has shown weight loss up to ~29% (vs. ~22% for tirzepatide), positioning retatrutide as the next-generation obesity gold standard for the late-2020s — and a structural pipeline answer to eventual tirzepatide patent expiry.

3. Mounjaro + Zepbound continuing to take share at scale — Lilly now holds ~57% of the GLP-1 / GIP market (up from ~53% in early 2025). Q1 2026 print delivered Mounjaro $8.66B (+125% YoY) and Zepbound $4.16B (+80% YoY) with total revenue growth of 56%. Sell-side has raised 2026 guidance and several analysts now model peak combined tirzepatide revenue >$70B by 2030.

4. Manufacturing capacity finally meeting demand — Lilly's $50B+ US capex program (Alabama, Pennsylvania, North Carolina, Europe) is unlocking 1.6x+ production growth and removing the volume cap that has constrained reported revenue. Supply elasticity is unlocking international launches (LATAM, Asia-Pacific, EU expansion) and the LillyDirect cash-pay channel.

Bear Case Risks

1. Most Favored Nation (MFN) drug pricing risk — Executive-order-driven pressure to reference-price US drugs to OECD averages would compress US tirzepatide net pricing by 30–50%. Even non-binding MFN frameworks have already contributed to a 13% realized price decline globally (-25% ex-US) in 2025. If codified into law or Medicare negotiation mechanics, US net pricing could compress materially through 2026–2028.

2. GLP-1 competition intensifying — Novo Nordisk is launching oral Wegovy globally, Pfizer (danuglipron successor), Roche (CT-388/996), Amgen (MariTide), and Viking Therapeutics (VK2735) all have Phase 2/3 obesity programs targeting 2027–2028 launches. The leadership window is real but not permanent; any safety signal on tirzepatide (e.g., FDA reporting on liver failure earlier in 2026 caused a sharp swing) could compress share.

3. Tirzepatide patent cliff in 2036 — Composition-of-matter expires 2036; biosimilar / generic erosion modeling typically prices in 50–70% sales decline over 3 years post-LOE. While follow-on patents and retatrutide should partially bridge, the long-duration earnings risk is real and underweighted in current consensus models.

4. Concentration risk + execution risk on capacity — Tirzepatide franchise represents >65% of Lilly's revenue. Any manufacturing setback (recall, supply chain disruption, FDA inspection findings) hits the entire growth thesis. Capex is running at ~17% of revenue — uncommonly high for big pharma — and any execution miss compresses returns on invested capital.

Upcoming Events

• Mid-April 2026: Orforglipron PDUFA decision (US oral GLP-1 approval)
• June 2026: Retatrutide TRANSCEND-T2D-1 Phase 3 data at ADA Scientific Sessions
• Q2 2026 earnings: Early August 2026
• H2 2026: Retatrutide Phase 3 obesity readouts; potential FDA filing
• 2026: Multiple label expansions (Zepbound for sleep apnea, MASH, etc.)
• Q3 2026 earnings: Late October 2026

Analyst Sentiment

Sell-side consensus skews Buy / Strong Buy (~85% positive). Average 12-month price targets cluster around $1,000–$1,250 (vs. current trading near $850–$900). Barclays raised PT to $1,400 in May 2026 citing tirzepatide momentum. The principal divergence is between near-term price-erosion bears (modeling MFN + payer pressure) and pipeline bulls (modeling orforglipron + retatrutide bridging tirzepatide).

Research Date

Generated: 2026-05-11